Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07773454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Trial Details
NCT Number NCT07773454
Lead Sponsor Exelixis
Conditions Cancer, Pediatric Cancer
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov